ArticleMolecular therapy. Oncology2026
Recombinant CALR polarizes and activates macrophages in tumors.
Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recombinant CALR as a novel immune adjuvant in tumor immunotherapy.Molecular therapy. Oncology · 2026Article
- Review
- Shared immune perturbations in hepatocellular carcinoma-depression comorbidity and synergistic immunotherapeutic effects of fluoxetine combined with anti-PD-1.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
We have created a recombinant form of calreticulin (CALR) to serve as an immune adjuvant. For many patients with immunogenically cold tumors, immunotherapies are ineffective. Simulating immunogenic cell death with damage-associated molecular patterns (DAMPs) has the potential to increase infiltration and activation of immune cells, characteristics of immunogenically hotter tumors. We hypothesized that delivery of recombinant CALR, a common DAMP, triggers leukocyte infiltration and activates tumor-infiltrating macrophages. To test this hypothesis, we developed a method to produce CALR with engineered
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.